Federal Register Notice: FDA has determined the regulatory review period for Forest Pharmaceuticals’ Namenda 5,001 days for extending patents which claim the human drug product. Namenda is indicated for treating moderate to severe dementia of the Alzheimer’s type. To view this notice, click here.
